LTK

Summary

LTK (leukocyte receptor tyrosine kinase, HGNC:6721) is a protein-coding gene on chromosome 15q15.1, encoding Leukocyte tyrosine kinase receptor (P29376). Receptor with a tyrosine-protein kinase activity.

The protein encoded by this gene is a member of the ros/insulin receptor family of tyrosine kinases. Tyrosine-specific phosphorylation of proteins is a key to the control of diverse pathways leading to cell growth and differentiation. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 4058 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 171 total
• Druggable target: yes — 43 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_002344

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6721
Approved symbol	LTK
Name	leukocyte receptor tyrosine kinase
Location	15q15.1
Locus type	gene with protein product
Status	Approved
Aliases	TYK1
Ensembl gene	ENSG00000062524
Ensembl biotype	protein_coding
OMIM	151520
Entrez	4058

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 14 protein_coding, 2 retained_intron

ENST00000263800, ENST00000355166, ENST00000453182, ENST00000561619, ENST00000563518, ENST00000569283, ENST00000897466, ENST00000897467, ENST00000897468, ENST00000953759, ENST00000953760, ENST00000953761, ENST00000953762, ENST00000953763, ENST00000953764, ENST00000953765

RefSeq mRNA: 3 — MANE Select: NM_002344 NM_001135685, NM_002344, NM_206961

CCDS: CCDS10077, CCDS10078, CCDS45237

Canonical transcript exons

ENST00000263800 — 20 exons

Exon	Start	End
ENSE00001029872	41507095	41507290
ENSE00001029873	41504342	41504432
ENSE00001029876	41504506	41504640
ENSE00001206223	41507562	41507657
ENSE00002606513	41513667	41513827
ENSE00003471724	41505713	41505777
ENSE00003487806	41511817	41511963
ENSE00003498743	41511164	41511346
ENSE00003504321	41505915	41506005
ENSE00003509312	41509031	41509129
ENSE00003540594	41504773	41504874
ENSE00003561833	41505208	41505305
ENSE00003577607	41511422	41511578
ENSE00003578928	41508069	41508221
ENSE00003587634	41503637	41504244
ENSE00003598502	41505401	41505530
ENSE00003642884	41504972	41505064
ENSE00003663659	41512707	41512878
ENSE00003681594	41512977	41513120
ENSE00003694646	41512115	41512265

Expression profiles

Bgee: expression breadth ubiquitous, 168 present calls, max score 90.63.

FANTOM5 (CAGE): breadth broad, TPM avg 0.5033 / max 24.8596, expressed in 197 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
149527	0.5033	197

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	90.63	gold quality
right lung	UBERON:0002167	85.26	gold quality
parotid gland	UBERON:0001831	83.77	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.60	gold quality
upper lobe of left lung	UBERON:0008952	81.45	gold quality
duodenum	UBERON:0002114	80.24	gold quality
heart right ventricle	UBERON:0002080	80.20	gold quality
upper lobe of lung	UBERON:0008948	79.89	gold quality
inferior olivary complex	UBERON:0002127	79.62	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	79.20	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	78.02	gold quality
rectum	UBERON:0001052	76.82	gold quality
jejunal mucosa	UBERON:0000399	76.20	gold quality
transverse colon	UBERON:0001157	76.10	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	76.05	gold quality
small intestine	UBERON:0002108	74.66	gold quality
small intestine Peyer’s patch	UBERON:0003454	74.62	gold quality
body of stomach	UBERON:0001161	72.89	gold quality
granulocyte	CL:0000094	72.66	gold quality
spleen	UBERON:0002106	72.60	gold quality
type B pancreatic cell	CL:0000169	71.86	gold quality
gall bladder	UBERON:0002110	71.75	gold quality
intestine	UBERON:0000160	71.50	gold quality
colon	UBERON:0001155	71.44	gold quality
olfactory bulb	UBERON:0002264	71.09	gold quality
right frontal lobe	UBERON:0002810	70.93	gold quality
Brodmann (1909) area 10	UBERON:0013541	70.87	gold quality
stomach	UBERON:0000945	70.70	gold quality
large intestine	UBERON:0000059	70.69	gold quality
tongue squamous epithelium	UBERON:0006919	70.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.16

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

11 targeting LTK, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-208B-5P	99.42	70.83	1952
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-6791-5P	99.16	65.92	1844
HSA-MIR-665	97.60	65.64	1781
HSA-MIR-320E	97.49	65.96	865
HSA-MIR-874-5P	96.93	63.92	1014

Literature-anchored findings (GeneRIF, showing 8)

• polymorphic LTKs cause up-regulation of the PI3K pathway and possibly form one genetic component of susceptibility to abnormal proliferation of self-reactive B cells in systemic lupus erythematosus (PMID:14695357)
• aberrant activation of LTK may contribute to neoplastic cell growth. (PMID:22347506)
• Only two related secreted factors, FAM150A and FAM150B (family with sequence similarity 150 member A and member B), stimulated LTK phosphorylation. (PMID:25331893)
• Data show FAM150B, which was named as augmentor-alpha (AUG-alpha), binds and activtes both anaplastic lymphoma kinase (ALK) and tyrosine kinase (LTK). (PMID:26630010)
• LTK-to-Sec12 signaling represents the first example of an endoplasmic reticulum-resident signaling module with the potential to regulate proteostasis. (PMID:31227593)
• Structural basis of cytokine-mediated activation of ALK family receptors. (PMID:34646012)
• The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. (PMID:34819663)
• Spindle cell neoplasms with novel LTK fusion - Expanding the spectrum of kinase fusion-positive soft tissue tumors. (PMID:38517106)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ltk	ENSMUSG00000027297
rattus_norvegicus	Ltk	ENSRNOG00000025130

Paralogs (53): INSRR (ENSG00000027644), MUSK (ENSG00000030304), FLT4 (ENSG00000037280), EPHA3 (ENSG00000044524), ROS1 (ENSG00000047936), ERBB3 (ENSG00000065361), TIE1 (ENSG00000066056), FGFR2 (ENSG00000066468), FGFR3 (ENSG00000068078), EPHA8 (ENSG00000070886), FGFR1 (ENSG00000077782), EPHA6 (ENSG00000080224), TYRO3 (ENSG00000092445), FLT1 (ENSG00000102755), MET (ENSG00000105976), EPHB6 (ENSG00000106123), PDGFRB (ENSG00000113721), EPHA4 (ENSG00000116106), TEK (ENSG00000120156), FLT3 (ENSG00000122025), KDR (ENSG00000128052), EPHB2 (ENSG00000133216), PDGFRA (ENSG00000134853), EPHA7 (ENSG00000135333), IGF1R (ENSG00000140443), NTRK3 (ENSG00000140538), ERBB2 (ENSG00000141736), EPHA2 (ENSG00000142627), EPHA5 (ENSG00000145242), EGFR (ENSG00000146648), EPHA1 (ENSG00000146904), NTRK2 (ENSG00000148053), MERTK (ENSG00000153208), EPHB1 (ENSG00000154928), KIT (ENSG00000157404), FGFR4 (ENSG00000160867), DDR2 (ENSG00000162733), RYK (ENSG00000163785), MST1R (ENSG00000164078), LMTK2 (ENSG00000164715)

Protein

Protein identifiers

Leukocyte tyrosine kinase receptor — P29376 (reviewed: P29376)

Alternative names: Protein tyrosine kinase 1

All UniProt accessions (2): P29376, H3BVG6

UniProt curated annotations — full annotation on UniProt →

Function. Receptor with a tyrosine-protein kinase activity. Following activation by ALKAL1 or ALKAL2 ligands at the cell surface, transduces an extracellular signal into an intracellular response. Ligand-binding to the extracellular domain induces tyrosine kinase activation, leading to activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. The exact function of this protein is not known; studies with chimeric proteins demonstrate its ability to promote growth and specifically neurite outgrowth, and cell survival. Involved in regulation of the secretory pathway involving endoplasmic reticulum (ER) export sites (ERESs) and ER to Golgi transport.

Subunit / interactions. Homodimer; homodimerizes following ligand-binding. Part of a complex including LTK, TNK2 and GRB2, in which GRB2 promotes LTK recruitment by TNK2.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in non-hematopoietic cell lines and T- and B-cell lines.

Post-translational modifications. Phosphorylated at tyrosine residues by autocatalysis, which activates kinase activity.

Disease relevance. Genetic variations in LTK that cause up-regulation of the PI3K pathway may possibly contribute to susceptibility to abnormal proliferation of self-reactive B-cells and, therefore, to systemic lupus erythematosus (SLE). SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue, thought to represent a failure of the regulatory mechanisms of the autoimmune system.

Activity regulation. Activated by ligand-binding, leading to homodimerization and autophosphorylation.

Similarity. Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.

Isoforms (5)

UniProt ID	Names	Canonical?
P29376-1	Lambda P2	yes
P29376-2	Lambda P1
P29376-3	Lambda P3
P29376-4	2
P29376-5	5

RefSeq proteins (3): NP_001129157, NP_002335, NP_996844 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR001245	Ser-Thr/Tyr_kinase_cat_dom	Domain
IPR002011	Tyr_kinase_rcpt_2_CS	Conserved_site
IPR008266	Tyr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR020635	Tyr_kinase_cat_dom	Domain
IPR050122	RTK	Family
IPR055163	ALK/LTK-like_GRD	Domain

Pfam: PF07714, PF12810

Enzyme classification (BRENDA):

• EC 2.7.10.1 — receptor protein-tyrosine kinase (BRENDA: 44 organisms, 214 substrates, 574 inhibitors, 11 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

4 substrates with measured Km, best-characterized 4. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0011–0.129	4
AC-DYFE-6-CHLORO-W-NHME	0.0051	1
AC-DYFGW-NHME	0.07	1
YFEW	0.232	1

Catalyzed reactions (Rhea), 1 shown:

• L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H(+) (RHEA:10596)

UniProt features (71 total): strand 17, sequence variant 8, splice variant 6, helix 6, mutagenesis site 5, compositionally biased region 4, sequence conflict 4, region of interest 4, glycosylation site 3, disulfide bond 3, binding site 2, topological domain 2, signal peptide 1, chain 1, active site 1, modified residue 1, transmembrane region 1, domain 1, turn 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
7NX1	X-RAY DIFFRACTION	1.3
7NX0	X-RAY DIFFRACTION	1.95

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P29376-F1	73.41	0.37

Antibody-complex structures (SAbDab): 1 — 7NX0

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 643 (proton acceptor)

Ligand- & substrate-binding residues (2): 516–524; 544

Post-translational modifications (1): 676

Disulfide bonds (3): 73–86, 168–179, 300–322

Glycosylation sites (3): 257, 380, 412

Mutagenesis-validated functional residues (5):

Position	Phenotype
241	abolished homodimerization following interaction with alkal1.
544	loss of interaction with plcg1, pi3-kinase subunit p85, ras gtpase-activating protein and raf1.
750	increases autophosphorylation and interaction with pi3-kinase subunit p85 (demonstrated with chimeric egfr-ltk).
753	abolishes interaction with pi3-kinase subunit p85, impairs pi3 kinase activity and leads to apoptosis (demonstrated with
862	impairs phosphorylation of cblc (demonstrated with chimeric egfr-ltk).

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-9842663	Signaling by LTK
R-HSA-162582	Signal Transduction
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases

MSigDB gene sets: 187 (showing top): MORF_RAGE, MORF_FLT1, BENPORATH_ES_WITH_H3K27ME3, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_NEUROGENESIS, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOMF_KINASE_ACTIVATOR_ACTIVITY, GCM_RING1, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_CELLULAR_RESPONSE_TO_RETINOIC_ACID, GOBP_REGULATION_OF_NEURON_DIFFERENTIATION, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4, GOBP_PHOSPHATIDYLINOSITOL_3_KINASE_PROTEIN_KINASE_B_SIGNAL_TRANSDUCTION, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_RESPONSE_TO_LIPID

GO Biological Process (12): protein phosphorylation (GO:0006468), signal transduction (GO:0007165), cell surface receptor protein tyrosine kinase signaling pathway (GO:0007169), cell population proliferation (GO:0008283), positive regulation of cardiac muscle cell apoptotic process (GO:0010666), positive regulation of neuron projection development (GO:0010976), peptidyl-tyrosine autophosphorylation (GO:0038083), regulation of cell population proliferation (GO:0042127), negative regulation of apoptotic process (GO:0043066), regulation of neuron differentiation (GO:0045664), positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051897), cellular response to retinoic acid (GO:0071300)

GO Molecular Function (9): protein kinase activity (GO:0004672), protein tyrosine kinase activity (GO:0004713), transmembrane receptor protein tyrosine kinase activity (GO:0004714), ATP binding (GO:0005524), receptor signaling protein tyrosine kinase activator activity (GO:0030298), nucleotide binding (GO:0000166), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (3): plasma membrane (GO:0005886), membrane (GO:0016020), signaling receptor complex (GO:0043235)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Signaling by Receptor Tyrosine Kinases	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular process	2
regulation of cellular process	2
phosphorylation	1
protein modification process	1
cell communication	1
signaling	1
cellular response to stimulus	1
enzyme-linked receptor protein signaling pathway	1
cardiac muscle cell apoptotic process	1
positive regulation of striated muscle cell apoptotic process	1
regulation of cardiac muscle cell apoptotic process	1
regulation of neuron projection development	1
neuron projection development	1
positive regulation of cell projection organization	1
peptidyl-tyrosine phosphorylation	1
protein autophosphorylation	1
cell population proliferation	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
neuron differentiation	1
regulation of cell differentiation	1
phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
positive regulation of intracellular signal transduction	1
response to retinoic acid	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
protein kinase activity	1
protein tyrosine kinase activity	1
transmembrane receptor protein kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
protein tyrosine kinase activator activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1

Protein interactions and networks

STRING

1070 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LTK	ALKAL2	Q6UX46	864
LTK	ALKAL1	Q6UXT8	793
LTK	CD5	P06127	550
LTK	PIK3R1	P27986	500
LTK	TNK2	Q07912	446
LTK	PTPRM	P28827	402
LTK	AXL	P30530	394
LTK	ALK	Q9UM73	391
LTK	EML4	Q9HC35	369
LTK	ANGPT1	Q15389	344
LTK	JAK2	O60674	337
LTK	ROS1	P08922	333
LTK	NPM1	P06748	317
LTK	PTN	P21246	317
LTK	MDK	P21741	310

IntAct

14 interactions, top by confidence:

A	B	Type	Score
LTK	ALKAL1	psi-mi:“MI:0407”(direct interaction)	0.590
LTK	ALKAL1	psi-mi:“MI:0914”(association)	0.590
ALKAL1	LTK	psi-mi:“MI:0915”(physical association)	0.590
PIK3R1	LTK	psi-mi:“MI:0914”(association)	0.570
LTK	EPHA2	psi-mi:“MI:0915”(physical association)	0.540
PTPN1	LTK	psi-mi:“MI:0407”(direct interaction)	0.440
LTK	PKM	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
LTK	PIK3R2	psi-mi:“MI:0914”(association)	0.420
LTK		psi-mi:“MI:0915”(physical association)	0.400
DUSP6	LTK	psi-mi:“MI:0915”(physical association)	0.370
MTMR14	LTK	psi-mi:“MI:0915”(physical association)	0.370
ALKAL2	LTK	psi-mi:“MI:0914”(association)	0.350
LTK	AIP	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (191): LTK (Synthetic Growth Defect), LTK (Reconstituted Complex), EGFR (Affinity Capture-Western), LTK (Affinity Capture-Western), SHC1 (Affinity Capture-Western), LTK (Affinity Capture-Western), DUSP6 (Two-hybrid), MTMR14 (Two-hybrid), LTK (Affinity Capture-MS), LTK (Affinity Capture-MS), LTK (Affinity Capture-MS), LTK (Affinity Capture-Western), PLCG1 (Affinity Capture-Western), PIK3R1 (Affinity Capture-Western), CBL (Biochemical Activity)

ESM2 similar proteins: A0EQL2, A2AJ76, A2AJA7, A6H8M9, A8T650, A8T682, A8T688, A8T6A6, D3ZLH5, F1QVU0, O08628, O75173, O88839, P04278, P08514, P08689, P0DV84, P15196, P20701, P29376, P32970, P38570, P60882, P80012, P97497, P97793, Q13444, Q15113, Q5RFQ8, Q5TM20, Q61398, Q63191, Q6UXC1, Q7Z304, Q7Z442, Q7Z7M0, Q8BNJ2, Q8CG85, Q8K1S7, Q8NBP7

Diamond homologs: F1QVU0, F8W3R9, O02466, O15146, O42127, O73798, O76411, O76997, P00529, P00530, P00541, P00542, P00543, P04629, P06213, P07332, P08069, P08922, P08923, P08941, P09208, P09760, P0DV84, P11362, P13368, P14238, P14616, P14617, P15127, P15208, P15209, P16092, P16591, P16879, P18460, P18461, P20806, P21802, P21803, P21804

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
LTK	“down-regulates activity”	PREB	phosphorylation
LTK	up-regulates	CBL	phosphorylation
LTK	up-regulates	IRS1	phosphorylation
LTK	up-regulates	PIK3CG	binding
LTK	up-regulates	SHC1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

171 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	148
Likely benign	6
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2564 predictions. Top by Δscore:

Variant	Effect	Δscore
15:41504337:CACA:C	donor_loss	1.0000
15:41504338:ACAC:A	donor_loss	1.0000
15:41504339:CACCT:C	donor_loss	1.0000
15:41504341:CCT:C	donor_loss	1.0000
15:41504353:A:AC	donor_gain	1.0000
15:41504354:C:CC	donor_gain	1.0000
15:41504500:A:C	donor_gain	1.0000
15:41504504:A:AC	donor_gain	1.0000
15:41504505:C:CC	donor_gain	1.0000
15:41504505:CA:C	donor_gain	1.0000
15:41504508:AGGC:A	donor_gain	1.0000
15:41504544:T:TA	donor_gain	1.0000
15:41504641:CTG:C	acceptor_loss	1.0000
15:41505204:TAACC:T	donor_loss	1.0000
15:41505205:AACCT:A	donor_loss	1.0000
15:41505206:A:AC	donor_loss	1.0000
15:41505207:C:T	donor_loss	1.0000
15:41505395:TCTCA:T	donor_loss	1.0000
15:41505396:CTCA:C	donor_loss	1.0000
15:41505397:TCA:T	donor_loss	1.0000
15:41505398:CA:C	donor_loss	1.0000
15:41505399:A:C	donor_loss	1.0000
15:41505400:C:CA	donor_loss	1.0000
15:41505527:CTTG:C	acceptor_gain	1.0000
15:41505528:TTG:T	acceptor_gain	1.0000
15:41505530:GC:G	acceptor_loss	1.0000
15:41505531:C:CC	acceptor_gain	1.0000
15:41505531:C:CG	acceptor_loss	1.0000
15:41505535:G:C	acceptor_gain	1.0000
15:41505535:G:GC	acceptor_gain	1.0000

AlphaMissense

5510 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:41504774:A:G	W707R	0.991
15:41504774:A:T	W707R	0.991
15:41505062:T:A	D643V	0.991
15:41505062:T:G	D643A	0.991
15:41504621:A:G	W714R	0.990
15:41504621:A:T	W714R	0.990
15:41504378:A:C	F770L	0.988
15:41504378:A:T	F770L	0.988
15:41504380:A:G	F770L	0.988
15:41504389:G:T	R767S	0.988
15:41504619:C:A	W714C	0.988
15:41504619:C:G	W714C	0.988
15:41504413:A:G	C759R	0.987
15:41504634:A:C	F709L	0.987
15:41504634:A:T	F709L	0.987
15:41504636:A:G	F709L	0.987
15:41505061:A:C	D643E	0.987
15:41505061:A:T	D643E	0.987
15:41512809:C:G	C86S	0.987
15:41512810:A:T	C86S	0.987
15:41505216:G:C	F639L	0.985
15:41505216:G:T	F639L	0.985
15:41505218:A:G	F639L	0.985
15:41504411:A:C	C759W	0.984
15:41504519:A:G	C748R	0.984
15:41504793:G:C	F700L	0.984
15:41504793:G:T	F700L	0.984
15:41504795:A:G	F700L	0.984
15:41505250:G:T	A628D	0.984
15:41505915:C:A	K544N	0.984

dbSNP variants (sampled 300 via entrez): RS1000070402 (15:41504249 A>G,T), RS1000207718 (15:41508692 C>G), RS1000349216 (15:41514230 C>T), RS1000448985 (15:41508401 A>C), RS1000522184 (15:41509715 C>A,T), RS1000590270 (15:41508414 C>T), RS1000789031 (15:41514151 G>T), RS1000979143 (15:41509510 T>C), RS1001332360 (15:41505768 C>G), RS1002249316 (15:41510702 C>T), RS1002559382 (15:41513298 C>A), RS1002604957 (15:41510997 G>A), RS1002720434 (15:41510314 C>T), RS1002984932 (15:41512228 T>C), RS1002986368 (15:41506800 G>C)

Disease associations

OMIM: gene MIM:151520 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST004862_101	Itch intensity from mosquito bite adjusted by bite size	3.000000e-06
GCST006463_20	Urinary albumin excretion (no hypertensive medication)	1.000000e-08
GCST009379_199	Type 2 diabetes	1.000000e-13
GCST009379_200	Type 2 diabetes	5.000000e-06
GCST010658_17	High density lipoprotein cholesterol levels	4.000000e-08
GCST90002389_295	Lymphocyte percentage of white cells	7.000000e-15

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0008377	mosquito bite reaction itch intensity measurement
EFO:0008378	mosquito bite reaction size measurement
EFO:0004285	albuminuria
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0007993	lymphocyte percentage of leukocytes

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5627 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

43 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 486,107 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1789941	RUXOLITINIB	4	11,547
CHEMBL1983268	ENTRECTINIB	4	3,510
CHEMBL24828	VANDETANIB	4	42,230
CHEMBL288441	BOSUTINIB	4	12,255
CHEMBL3286830	LORLATINIB	4	3,598
CHEMBL3301622	GILTERITINIB	4	2,395
CHEMBL3545311	BRIGATINIB	4	5,634
CHEMBL3622821	UPADACITINIB	4	2,726
CHEMBL477772	PAZOPANIB	4	15,540
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL553	ERLOTINIB	4	108,300
CHEMBL601719	CRIZOTINIB	4	14,403
CHEMBL608533	MIDOSTAURIN	4	7,259
CHEMBL939	GEFITINIB	4	117,814
CHEMBL1879463	DACTOLISIB	3	7,988
CHEMBL223360	LINIFANIB	3	3,925
CHEMBL31965	CANERTINIB	3	8,083
CHEMBL428690	ALVOCIDIB	3	27,781
CHEMBL483158	ALISERTIB	3
CHEMBL491473	CEDIRANIB	3
CHEMBL603469	LESTAURTINIB	3
CHEMBL103667	DORAMAPIMOD	2
CHEMBL1230609	FORETINIB	2
CHEMBL1721885	SU-014813	2
CHEMBL1738757	REBASTINIB	2
CHEMBL1967878	CENISERTIB	2
CHEMBL1980297	ILORASERTIB	2
CHEMBL215152	DEFOSBARASERTIB	2

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family

Most potent curated ligand interactions (4 total), top 4:

Ligand	Action	Affinity	Parameter
gilteritinib	Inhibition	9.7	pIC50
compound 8e [PMID: 24432909]	Inhibition	8.7	pIC50
belizatinib	Inhibition	8.6	pKd
compound 20 [PMID: 30998356]	Inhibition	6.25	pKi

ChEMBL bioactivities

251 potent at pChembl≥5 of 288 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.46	IC50	0.35	nM	GILTERITINIB
9.25	IC50	0.567	nM	CHEMBL4546504
9.02	Kd	0.95	nM	TAE-684
8.96	Kd	1.1	nM	CHEMBL464552
8.80	Ki	1.585	nM	CHEMBL461876
8.80	Ki	1.585	nM	ENTRECTINIB
8.74	IC50	1.8	nM	CRIZOTINIB
8.70	IC50	2	nM	CHEMBL3128069
8.70	Ki	1.995	nM	CHEMBL1164265
8.60	Kd	2.5	nM	CHEMBL2172308
8.60	Ki	2.512	nM	CHEMBL1825138
8.57	IC50	2.7	nM	LORLATINIB
8.57	Ki	2.7	nM	LORLATINIB
8.57	IC50	2.7	nM	CHEMBL5712062
8.50	Ki	3.162	nM	CHEMBL1980995
8.50	Ki	3.162	nM	CHEMBL1993661
8.44	IC50	3.6	nM	STAUROSPORINE
8.40	IC50	4	nM	CHEMBL4473365
8.40	Ki	3.981	nM	CHEMBL1980329
8.20	IC50	6.3	nM	CHEMBL4764610
8.10	Ki	7.943	nM	CHEMBL458997
8.09	Kd	8.2	nM	CHEMBL2172315
8.00	Ki	10	nM	CHEMBL1974328
8.00	Ki	10	nM	CHEMBL1164180
7.92	Kd	12	nM	CRIZOTINIB
7.90	Ki	12.59	nM	CHEMBL1977138
7.90	Ki	12.59	nM	CHEMBL1973961
7.85	IC50	14	nM	BRIGATINIB
7.80	Ki	15.85	nM	CENISERTIB
7.80	Ki	15.85	nM	CHEMBL1979690
7.72	IC50	19	nM	STAUROSPORINE
7.70	Ki	19.95	nM	CHEMBL1989708
7.70	Ki	19.95	nM	CHEMBL1988581
7.60	Ki	25.12	nM	CHEMBL21156
7.60	Ki	25.12	nM	CHEMBL1967998
7.60	Ki	25.12	nM	CHEMBL1997335
7.54	IC50	29.2	nM	STAUROSPORINE
7.54	IC50	29	nM	CHEMBL1235786
7.54	Kd	29	nM	CHEMBL1235786
7.50	Ki	31.62	nM	CHEMBL2002099
7.50	Ki	31.62	nM	CHEMBL2004290
7.50	Ki	31.62	nM	CHEMBL1981047
7.50	Ki	31.62	nM	CHEMBL2007421
7.44	IC50	36.3	nM	STAUROSPORINE
7.43	Kd	37	nM	STAUROSPORINE
7.40	Ki	39.81	nM	CHEMBL1983111
7.40	Ki	39.81	nM	ILORASERTIB
7.37	IC50	43.1	nM	CHEMBL3735648
7.34	IC50	45.3	nM	CHEMBL4067871
7.30	Ki	50.12	nM	CHEMBL1825138

PubChem BioAssay actives

79 with measured affinity, of 392 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
Gilteritinib	1894600: Inhibition of LTK (unknown origin) in presence of ATP	ic50	0.0003	uM
4-[[5-chloro-4-(4-hydroxy-4-methylcyclohexyl)oxy-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-N,N-dimethyl-3-[(2R)-1,1,1-trifluoropropan-2-yl]oxybenzamide	1551609: Inhibition of recombinant human GST-tagged LTK cytoplasmic domain (450 to 864 residues) expressed in baculovirus expression system by Z’-LYTE assay	ic50	0.0006	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	624743: Binding constant for LTK kinase domain	kd	0.0009	uM
2-[[2-[[1-[2-(dimethylamino)acetyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide	624743: Binding constant for LTK kinase domain	kd	0.0011	uM
Crizotinib	2161832: Inhibition of human N-terminal GST-fused LTK catalytic domain (498 to 796 residues) expressed in baculovirus expression system using Srctide as substrate measured after 1 hr by off-chip mobility shift assay relative to control	ic50	0.0018	uM
(2R)-2-[5-[6-amino-5-[(1R)-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridinyl]-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol	1074705: Inhibition of LTK (unknown origin) using Km levels of ATP	ic50	0.0020	uM
4-fluoro-N-[6-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-1-[4-(propan-2-ylcarbamoyl)cyclohexyl]benzimidazol-2-yl]benzamide	703117: Binding affinity to human LTK by Ambit titration assay	kd	0.0025	uM
(16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,11,13,18,20-heptaene-3-carbonitrile	2187697: Inhibition of GST-tagged recombinant LTK (450 to 864 residues) (unknown origin) expressed in Insect cell	ic50	0.0027	uM
Lorlatinib	1153150: Inhibition of LTK (unknown origin) by TR-FRET-based Z’-LYTE assay	ic50	0.0027	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1308967: Inhibition of LTK (unknown origin) incubated for 1 hr by spectrophotometric analysis	ic50	0.0036	uM
N-[5-[[5-chloro-4-(2-propan-2-ylsulfonylanilino)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide	1584373: Inhibition of recombinant GST-tagged human LTK cytoplasmic domain (440 to 864 residues) expressed in baculovirus expression system by Z-LYTE assay	ic50	0.0040	uM
4-fluoro-2-methoxy-11-oxo-5-propan-2-yl-3-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-6H-indolo[2,3-b]quinoline-8-carbonitrile	1700707: Inhibition of human LTK	ic50	0.0063	uM
3,5-difluoro-N-[6-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-1-[4-(propan-2-ylcarbamoyl)cyclohexyl]benzimidazol-2-yl]benzamide	703117: Binding affinity to human LTK by Ambit titration assay	kd	0.0082	uM
Brigatinib	2182803: Inhibition of human LTK using EAIYAAPFAKKK as substrate in presence of [gamma33P]-ATP by HotSpot assay	ic50	0.0140	uM
1-[3-methoxy-4-[[4-(2-propan-2-ylsulfonylanilino)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]phenyl]piperidin-4-ol	2185959: Binding affinity to LTK (unknown origin) assessed as dissociation constant by Ambit kinase binding assay	kd	0.0290	uM
6,6-dimethyl-8-[1-(oxan-4-ylmethyl)piperidin-4-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile	1312459: Inhibition of recombinant LTK (unknown origin) using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA	ic50	0.0431	uM
4-chloro-2-[5-[[(1R)-2-hydroxy-1-phenylethyl]amino]-3-isoquinolin-6-yl-2-pyridinyl]phenol	1450723: Inhibition of recombinant LTK (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA	ic50	0.0453	uM
N-[2-hydroxy-3-[C-phenyl-N-[4-(piperidin-1-ylmethyl)phenyl]carbonimidoyl]-1H-indol-5-yl]ethanesulfonamide	389052: Binding affinity to human LTK	kd	0.0520	uM
2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine	2161832: Inhibition of human N-terminal GST-fused LTK catalytic domain (498 to 796 residues) expressed in baculovirus expression system using Srctide as substrate measured after 1 hr by off-chip mobility shift assay relative to control	ic50	0.0610	uM
5-[(1R)-1-(3,5-dichloro-4-pyridinyl)ethoxy]-3-[6-(2-methylsulfonyl-2,6-diazaspiro[3.3]heptan-6-yl)-3-pyridinyl]-1H-indazole	2118406: Inhibition of human LTK by KINOMEscan analysis	ic50	0.0650	uM
5-fluoro-2-[5-[[(1R)-2-hydroxy-1-phenylethyl]amino]-3-(3-methyl-2H-indazol-5-yl)-2-pyridinyl]phenol	1450723: Inhibition of recombinant LTK (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA	ic50	0.0685	uM
1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	624743: Binding constant for LTK kinase domain	kd	0.1100	uM
4-fluoro-2-[5-[[(1R)-2-hydroxy-1-phenylethyl]amino]-3-(3-methyl-2H-indazol-5-yl)-2-pyridinyl]phenol	1450723: Inhibition of recombinant LTK (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA	ic50	0.1229	uM
methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate	624743: Binding constant for LTK kinase domain	kd	0.1500	uM
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	435168: Binding constant for LTK kinase domain	kd	0.1600	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526243: Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged LTK (unknown origin) (498 to 796 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.1930	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-methylamino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526243: Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged LTK (unknown origin) (498 to 796 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	kd	0.1930	uM
4-[4-[(3-tert-butyl-1-quinolin-6-ylpyrazol-5-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide	2168264: Inhibition of human wild type TYK1 using PolyEY as substrate preincubated for 2 hrs followed by ATP addition and measured every 2 mins for 2.5 hrs by spectrophotometric analysis	ic50	0.2600	uM
4-chloro-2-[5-[[(1R)-2-hydroxy-1-phenylethyl]amino]-3-(3-methyl-2H-indazol-5-yl)-2-pyridinyl]phenol	1450723: Inhibition of recombinant LTK (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA	ic50	0.2995	uM
N-propyl-4-[[4-(2,2,2-trifluoroethylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]benzamide	1440133: Inhibition of LTK (unknown origin) after 60 mins by TR-FRET assay	ic50	0.3600	uM
Ruxolitinib	624743: Binding constant for LTK kinase domain	kd	0.4400	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	507592: Binding affinity to LTK	kd	0.4900	uM
1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea	435168: Binding constant for LTK kinase domain	kd	0.5500	uM
Vandetanib	435168: Binding constant for LTK kinase domain	kd	0.5500	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	624743: Binding constant for LTK kinase domain	kd	0.8000	uM
Erlotinib	435168: Binding constant for LTK kinase domain	kd	0.8900	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	624743: Binding constant for LTK kinase domain	kd	0.9200	uM
4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide	624743: Binding constant for LTK kinase domain	kd	1.2000	uM
2-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol	624743: Binding constant for LTK kinase domain	kd	1.4000	uM
1-[3-tert-butyl-1-(4-methylphenyl)pyrazol-5-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea	435168: Binding constant for LTK kinase domain	kd	1.4000	uM
Sunitinib	435168: Binding constant for LTK kinase domain	kd	1.8000	uM
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one	435168: Binding constant for LTK kinase domain	kd	2.2000	uM
Upadacitinib	2189521: Inhibition of LTK (unknown origin) by TR-FRET assay	ic50	2.7000	uM
Bosutinib	624743: Binding constant for LTK kinase domain	kd	3.0000	uM
Midostaurin	435168: Binding constant for LTK kinase domain	kd	3.0000	uM
2-[3-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-5-yl]-N-(3-fluorophenyl)acetamide	435168: Binding constant for LTK kinase domain	kd	3.2000	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	435168: Binding constant for LTK kinase domain	kd	4.2000	uM
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline	624743: Binding constant for LTK kinase domain	kd	4.3000	uM
N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide	624743: Binding constant for LTK kinase domain	kd	5.1000	uM
5,5-dimethyl-8-[[4-(2,2,2-trifluoroethylamino)furo[3,2-d]pyrimidin-2-yl]amino]-1H-4,1-benzoxazepin-2-one	1440133: Inhibition of LTK (unknown origin) after 60 mins by TR-FRET assay	ic50	5.1100	uM

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation	3
aristolochic acid I	increases expression	1
fluorene-9-bisphenol	decreases expression	1
arsenite	increases methylation	1
perfluorooctanoic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
Fulvestrant	decreases methylation	1
Arsenic	increases methylation	1
Benzo(a)pyrene	affects methylation	1
Diazinon	increases methylation	1
Rifampin	increases expression	1
Smoke	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	increases expression	1
Triclosan	decreases expression	1
Asbestos, Serpentine	decreases methylation	1
Asbestos, Crocidolite	decreases methylation	1
Asbestos, Amosite	decreases methylation	1
Okadaic Acid	increases expression	1

ChEMBL screening assays

248 unique, capped per target: 246 binding, 1 functional, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1035899	Binding	Binding affinity to human LTK at 10 uM relative to control	Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. — J Med Chem
CHEMBL1964115	Functional	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: LTK	PubChem BioAssay data set
CHEMBL4023734	ADMET	Inhibition of recombinant human cytoplasmic GST-tagged LTK expressed in baculovirus at 1 uM by Z’-LYTE assay	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development. — J Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SW07	HAP1 LTK (-) 1	Cancer cell line	Male
CVCL_SW08	HAP1 LTK (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.